Reduced sulphoxidation capacity in D-penicillamine induced myasthenia gravis.
Myasthenia gravis may be observed due to treatment with penicillamine (D-PA). The sulphoxidation capacity was measured in nine Swedish patients with rheumatoid arthritis (RA) who had developed myasthenia gravis toward D-PA. The results show that in eight of nine patients tested, this parameter was markedly reduced. A patient with poor sulphoxidation capacity has a twelve-fold greater risk of developing this rare side effect. The significance of this is discussed.
Seideman
P
P
Department of Internal Medicine, Karolinska Institute, Danderyd, Sweden.
Ayesh
R
R
D000328:Adult; D000368:Aged; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000378:metabolism; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009157:Myasthenia Gravis / Q000139:chemically induced* / Q000652:urine; D010396:Penicillamine / Q000009:adverse effects* / Q000378:metabolism / Q000627:therapeutic use; D013454:Sulfoxides / Q000378:metabolism* / Q000652:urine
D013454:Sulfoxides; D010396:Penicillamine